Navigation Links
Randomized Study Comparing Cell Therapeutics' OPAXIO (Paclitaxel Poliglumex) and Radiotherapy to Standard of Care Temozolomide and Radiotherapy Treatment Open for Enrollment
Date:8/18/2011

leasing the paclitaxel chemotherapy.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com/.

Sign up for email alerts and get RSS feeds at CTI's Web site, http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of OPAXIO include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with OPAXIO in particular, including, without limitation, the potential failure of OPAXIO to prove safe and effective and/or less toxic and effective for the treatment of newly diagnosed high-grade malignant brain tumors such as GBM, including when combined with TMZ and RT, the potential failure of OPAXIO when combined with TMZ and RT to provide PFS and OS responses to newly-diagnosed high-grade malignant brain tumors such as GBM, that the results of the new OPAXIO study may not be positive or be used to plan a phase III study of OPAXIO for approval for use in treating newly diagnosed GBM, that CTI cannot predict or guarantee the pace of patient enrollment in the phase II clinical study comparing OPAXIO to TMZ, Brown  and CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling CTI's product candidates such as OPAXIO, and the risk factors listed or described from tim
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
2. Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone
3. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
4. YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
5. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
6. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
7. Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans
8. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
9. Harvest Technologies Announces Completion of Patient Enrollment in its Randomized, Controlled, Double Blind Multicenter IDE Non-Reconstructable Critical Limb Ischemia Trial
10. NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
11. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... San Francisco, CA (PRWEB) May 23, 2013 ... do-it-yourselfers who encourage all types of inventions. They focus ... we’re now noticing this community gravitate toward bringing their ... community, the DIY Biology Movement, works on making projects ... sequencing the DNA of plants to make them glow ...
(Date:5/23/2013)... 2013  Saddleback Memorial Medical Center in ... hospital on the West Coast to perform a hysterectomy ... provides women with a state-of-the-art, minimally invasive approach to ... , M.D., a highly regarded Orange ... of minimally invasive surgery at Saddleback Memorial, led the ...
(Date:5/23/2013)... 2013 On April 19th the ... to search for the growing antibiotic resistant bacteria that ... a year long study were released late last month ... meats, over previous years. For those suffering from bacteria ... antibiotic resistant bacteria in food, may eventually help breed ...
(Date:5/23/2013)... Washington, DC (PRWEB) May 23, 2013 ... African-Americans in STEM industries, Black Data Processing Associates (BDPA), ... Day on June 8, 2013. This all-day event will ... arena, and learn the ins and outs from many ... to 3 p.m. at the New Jersey Institute of ...
Breaking Biology Technology:Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013 2
... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it ... and Drug Administration (FDA) for the Elecsys Anti-HBc IgM assay for ... 601 and MODULAR ANALYTICS E170 analyzers. ... panel within the hepatitis menu on Roche,s family of immunoassay analyzers. ...
... Selexis SA , a global life science company with ... manufacturing of therapeutic proteins announced today that CSL Limited (ASX:CSL ... the preclinical development of a therapeutic antibody anticipated ... This commercial license agreement provides CSL with the rights to ...
... Rising star Divine Skin Inc. (DSKX), which has been expanding ... long-time leader in the cosmetics industry, to become its president. ... Divine Skin because I believe their innovative products are unmatched ... with a ,wow, factor." A dozen Divine ...
Cached Biology Technology:Roche Submits Acute Hepatitis B Test to FDA for Premarket Approval 2CSL Limited Signs Commercial License Agreement with Selexis SA 2Robin Powell Becomes President at Biotech Leader Divine Skin (DSKX) 2
(Date:5/22/2013)... working to improve durability in fuel cell powered ... have discovered links between electrode degradation processes and ... the effects of electrode degradation stressors in the ... lifetime. , The findings of the study, led ... latest in a long-term study at Burnaby-based Ballard ...
(Date:5/22/2013)... Md. (May 22, 2013)The omega 3 fatty acids in ... cardiovascular diseaseso much so that the American Heart Association ... a week, particularly fatty varieties rich in omega 3s. ... a mystery. In a new study, scientists led by ... on this phenomenon by providing evidence that fish oil ...
(Date:5/22/2013)... in cellular DNA can endanger the whole organism, as ... at Ludwig-Maximilians-Universitaet (LMU) in Munich now report how byproducts ... helix. , The DNA in our cells controls the ... bodies. The instructions for this are encoded in the ... the bases adenine (A), cytosine (C), guanine (G) and ...
Breaking Biology News(10 mins):Tests lead to doubling of fuel cell life 2Fish oil may help the heart beat mental stress 2DNA damage: The dark side of respiration 2
... from the electrical signals emitted by diverse brain cells ... level, scientists struggle to explain the mind. Worse yet, ... in patients with ailments such as depression or Parkinson's ... issue of Nature describes a technique to directly control ...
... found early indicators of inflammation ?potential warning signs ?in ... findings could someday lead to early detection and prevention ... tendonitis. , The new study from Temple University ... doctoral student, Stephen Carp, in the March issue of ...
... for Cancer Research (LICR) and the University of California, ... breakthrough in identifying functional elements in the human genome, ... Genetics. , While the DNA sequence can identify ... the more fundamental questions of 'how,' 'when' and 'where' ...
Cached Biology News:A 'traffic light' for neurons means 'go' for improving brain research 2A 'traffic light' for neurons means 'go' for improving brain research 3A 'traffic light' for neurons means 'go' for improving brain research 4Red flag for repetitive stress injuries identified for first time in humans 2Beyond the DNA: Chemical signatures reveal genetic switches in the genome 2
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
CD69/CD3 50 tests...
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Biology Products: